Virtanen MPO, Airaksinen J, Niemelä M, et al. - Using data from the FinnValve registry [includes data on 6,463 patients who had transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) with bioprosthesis between 2008 and 2017], researchers assessed the outcome of TAVI and SAVR in low-risk patients without coronary artery disease (CAD). They focused on the result of low operative risk as defined by STS-PROM score < 3% and absence of CAD, previous stroke and other relevant comorbidities. The criteria for inclusion were TAVI with third-generation prostheses and SAVR with Perimount Magna Ease or Trifecta prostheses. Experts analyzed 30-day and 3-year all-cause mortality. Overall 140 pairs with similar baseline features were examined after propensity score matching. In both TAVI and SAVR cohorts, the 30-day mortality was estimated to be 2.1%, among these matched pairs, and 3-year mortality was estimated to be 17.0% and 14.6% following TAVI and after SAVR, respectively. Following TAVI, they reported lower rates of bleeding and atrial fibrillation, as well as a shorter hospital stay. In low-risk patients without CAD, similar early and mid-term survival was observed with TAVI using third-generation prostheses vs SAVR.